Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aura Biosciences (AURA) Treasury Shares (2021 - 2026)

Aura Biosciences filings provide 6 years of Treasury Shares readings, the most recent being $3.3 million for Q1 2026.

  • Quarterly Treasury Shares rose 19.42% to $3.3 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $3.3 million through Mar 2026, up 19.42% year-over-year, with the annual reading at $2.7 million for FY2025, 69.33% up from the prior year.
  • Treasury Shares hit $3.3 million in Q1 2026 for Aura Biosciences, up from $2.7 million in the prior quarter.
  • Across five years, Treasury Shares topped out at $3.3 million in Q1 2026 and bottomed at $153950.0 in Q4 2022.
  • Average Treasury Shares over 5 years is $1.5 million, with a median of $1.6 million recorded in 2024.
  • The largest annual shift saw Treasury Shares plummeted 33.62% in 2022 before it surged 610.23% in 2023.
  • Aura Biosciences' Treasury Shares stood at $153950.0 in 2022, then surged by 610.23% to $1.1 million in 2023, then soared by 45.33% to $1.6 million in 2024, then skyrocketed by 69.33% to $2.7 million in 2025, then increased by 22.13% to $3.3 million in 2026.
  • Per Business Quant, the three most recent readings for AURA's Treasury Shares are $3.3 million (Q1 2026), $2.7 million (Q4 2025), and $2.8 million (Q3 2025).